Forekomsten af brystsymptomer og uterin blødning var hos raloxifenbehandlede kvinder signifikant lavere end hos kvinder, som blev behandlet med den ene eller anden form for hormonal substitutions - behandling.
The incidence of breast symptoms and uterine bleeding in raloxifene treated women was significantly lower than in women treated with either form of HRT.